Transcatheter Cardiovascular Therapeutics (TCT) 2021

6-month single antiplatelet regimen after DAPT post-PCI may reduce GI injury

Roshini Claire Anthony, 20211125180001

Among patients who received 6 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), switching to a single antiplatelet therapy (SAPT) regimen for another 6 months resulted in less gastrointestinal (GI) injury than continuing DAPT, results of the OPT-PEACE trial showed.

Amphilimus-eluting stents: As good as zotarolimus-eluting stents in patients with diabetes?

Roshini Claire Anthony, 20211122160001

The use of amphilimus-eluting stents (AES) in patients with diabetes mellitus undergoing percutaneous revascularization was less likely to result in target lesion or target vessel failure compared with zotarolimus-eluting stents (ZES) at 1 year, according to findings of the SUGAR trial presented at TCT 2021.

1-month DAPT post-PCI: Where does the limit lie?

Pearl Toh, 20211120130010

Dropping aspirin after 1 month of DAPT* with clopidogrel and aspirin following PCI** reduces major bleeding events without increasing cardiovascular (CV) events compared with continuing DAPT for 12 months, regardless of bleeding risk and complexity of PCI, according to a pooled analysis of the STOPDAPT-2 and STOPDAPT-2 ACS trials presented at TCT 2021.

Rivaroxaban + aspirin combo halves stroke risk in COMPASS

No trade-off between bleeding and ischaemic risk with abbreviated DAPT

Elvira Manzano, 20211119000000

Stopping dual antiplatelet therapy (DAPT) after 1 month appeared safe in high-bleeding risk (HBR) patients with acute myocardial infarction (MI) who were implanted with a newer coronary stent, a prespecified subanalysis of the MASTER DAPT* trial has shown.

Similar long-term outcomes with iFR- vs FFR-guided revascularization

Elaine Soliven, 20211118000000

The use of instantaneous wave-free ratio (iFR) to guide revascularization decisions continued to show similar outcomes in terms of all-cause mortality, myocardial infarction (MI), or unplanned revascularization in patients with stable angina or acute coronary syndrome (ACS) compared with fractional flow reserve (FFR) at 5 years, according to the iFR-SWEDEHEART* study presented at TCT 2021.

Pacemaker-based cardiac neuromodulation therapy lowers SBP, pulse pressure in patients with ISH

Elaine Soliven, 20211117000000

Adding BackBeat cardiac neuromodulation therapy™ (Backbeat CNT), a pacemaker-based treatment for hypertension, on top of medical therapy significantly reduces systolic blood pressure (SBP) and pulse pressure, without reducing diastolic blood pressure (DBP), compared with medical therapy alone in patients with isolated systolic hypertension (ISH), according to a study presented at TCT 2021.

SURTAVI: TAVR matches SAVR through 5 years in intermediate-risk AS patients

Pearl Toh, 20211116150000

The noninferiority finding between transcatheter vs surgical aortic valve replacement (TAVR vs SAVR) in intermediate-risk patients with severe aortic stenosis (AS) holds up through 5 years, according to long-term data of the SURTAVI trial presented at TCT 2021, providing reassurance that the less invasive procedure performs just as good in the elderly population.

TiNO-coated stent maintains edge over drug-eluting stent for ACS

Audrey Abella, 20211116100000

The 3-year outcomes of the TIDES-ACS* trial continued to reflect favourable outcomes with the titanium-nitride-oxide (TiNO)-coated bioactive stent compared with a platinum-chromium-based biodegradable-polymer everolimus-eluting stent (EES) for patients with acute coronary syndrome (ACS).

Medicine uptitration amps up RDN benefit for drug-resistant hypertension

Audrey Abella, 20211114100000

In patients with multidrug-resistant hypertension (HTN), the blood pressure (BP)-lowering benefit of renal denervation (RDN) achieved at 2 months was amplified when a stepped-care medication escalation protocol was added between 2 and 6 months, updates from the RADIANCE-HTN TRIO trial have shown.